Risk of bone metastases on [18F]NaF PET/CT in 734 patients with newly diagnosed prostate cancer
European Journal of Nuclear Medicine and Molecular Imaging · 2026-11 · 53 (13) · 8488-8496
DOI: 10.1007/s00259-026-08148-y ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 05.09.2026. Verfasst von Claus Madsen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Copenhagen University Hospital Herlev and Gentofte, Borgmester Ib Juuls Vej 31, 2730, Herlev, Denmark. claus.madsen@r…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Bone Neoplasms, Positron Emission Tomography Computed Tomography, Sodium Fluoride. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Copenhagen University.
Abstract (Originalsprache)
Purpose
International guidelines recommend assessment for bone metastases in patients with high-risk prostate cancer (PC) and those with unfavourable intermediate-risk disease. These recommendations are largely based on studies using planar bone scintigraphy. We aimed to assess the diagnostic accuracy of [ 18 F]sodium fluoride ([ 18 F]NaF) PET/CT in newly diagnosed PC. We also evaluated the clinical utility of routine bone imaging in patients with unfavourable intermediate-risk disease and International Society of Urological Pathology grade group (ISUP GG) 3.
Methods
This retrospective single-center study included 734 consecutive patients with newly diagnosed PC who underwent [ 18 F]NaF PET/CT for primary staging. Patients were classified according to the current European Association of Urology risk classification, with the intermediate-risk subgroup restricted to patients with ISUP GG 3. All scan reports were retrospectively reviewed, and patient-level findings regarding bone metastases were validated against a reference standard based on follow-up imaging and clinical data. Sensitivity, specificity, and predictive values were calculated.
Results
Of the 734 patients, 607 (83%) had high-risk disease and 127 (17%) had intermediate-risk disease with ISUP GG 3. Overall, bone metastases were detected in 225 patients (31%). Among high-risk patients, 224 (37%) had bone metastases, whereas only 1 of 127 intermediate-risk patients (0.8%) had bone metastases on [ 18 F]NaF PET/CT. Follow-up identified one additional potential false-negative case in the intermediate-risk group. Among patients with a conclusive reference standard ( n = 689), sensitivity and specificity were 0.90 and 0.99, respectively. Conclusion [ 18 F]NaF PET/CT demonstrates high diagnostic accuracy for the detection of bone metastases in newly diagnosed PC. However, given the very low prevalence of bone metastases, its clinical utility in patients with unfavourable intermediate-risk disease and ISUP GG 3 appears limited.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Copenhagen University Hospital Herlev and Gentofte, Borgmester Ib Juuls Vej 31, 2730, Herlev, Denmark. claus.madsen@regionh.dk.
- Department of Nuclear Medicine and Clinical Cancer Research Centre, Aalborg University Hospital, Hobrovej 18-22, 9000, Aalborg, Denmark.
- Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
- Department of Urology, Copenhagen University Hospital Herlev and Gentofte, Borgmester Ib Juuls Vej 1, 2730, Herlev, Denmark.
- Department of Nuclear Medicine, Copenhagen University Hospital Herlev and Gentofte, Borgmester Ib Juuls Vej 31, 2730, Herlev, Denmark.
- Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
Förderung
- Copenhagen University
Zitieren
APA
Madsen, C., Zacho, H. D., Bisbjerg, R., Fuglø, D., & Østergren, P. B. (2026). Risk of bone metastases on [18F]NaF PET/CT in 734 patients with newly diagnosed prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 53(13), 8488-8496. https://doi.org/10.1007/s00259-026-08148-y
Vancouver
Madsen C, Zacho HD, Bisbjerg R, Fuglø D, Østergren PB. Risk of bone metastases on [18F]NaF PET/CT in 734 patients with newly diagnosed prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(13):8488-8496. doi:10.1007/s00259-026-08148-y
BibTeX
@article{Madsen2026,
author = {Madsen, Claus and Zacho, Helle D and Bisbjerg, Rasmus and Fuglø, Dan and Østergren, Peter B},
title = {Risk of bone metastases on [18F]NaF PET/CT in 734 patients with newly diagnosed prostate cancer},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2026},
volume = {53},
number = {13},
pages = {8488--8496},
doi = {10.1007/s00259-026-08148-y}
}
EUVIMED